Spots Global Cancer Trial Database for natural killer cells
Every month we try and update this database with for natural killer cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation | NCT04796363 | Analgesia Breast Cancer | Erector Spinae ... Standard Genera... | 20 Years - 50 Years | Alexandria University | |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | NCT01385423 | Acute Myelogeno... Myelodysplastic... | Preparative Reg... Intravenous Rec... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | NCT00660166 | Lymphoma Myeloma Leukemia | NK-Cell Infusio... | 13 Years - 70 Years | Tufts Medical Center | |
| Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors | NCT05887882 | Pediatric Brain... Recurrent Pedia... Pediatric Supra... | Universal Donor... Implantation | 1 Year - 39 Years | University of California, San Francisco | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety Study of Adoptive Transfer of Autologous IKDC-like Cells | NCT02661685 | Neoplasm Metast... | autologous IKDC... | 21 Years - 75 Years | National Defense Medical Center, Taiwan | |
| Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery | NCT02326727 | Colonic Neoplas... | Ropivacaine Fentanyl Propofol Isoflurane Nitrous Oxide | 18 Years - | Hillel Yaffe Medical Center | |
| Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | NCT01181258 | Non-Hodgkin Lym... Chronic Lymphoc... | Rituximab Interleukin-2 Natural killer ... Cyclophosphamid... Methylprednisol... Fludarabine | - | Masonic Cancer Center, University of Minnesota | |
| Mechanisms of Immunosurveillance for Lung Cancer | NCT01710319 | Lung Cancer | blood draw | 18 Years - | Washington University School of Medicine | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | NCT04245865 | Colorectal Canc... | Fluorouracil Calcium folinat... Oxaliplatin Bevacizumab Capecitabine Tocotrienol Placebo | 18 Years - | Vejle Hospital | |
| ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | NCT01478074 | Acute Myeloid L... | G-CSF Cytarabine Fludarabine Donor Natural K... ALT-801 | 2 Years - 59 Years | Altor BioScience | |
| Natural Killer-cell Therapy for Acute Myeloid Leukemia | NCT04347616 | Acute Myeloid L... Acute Myeloid L... | UCB-NK cells IL-2 | 18 Years - | Radboud University Medical Center | |
| CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | NCT05207722 | Metastatic HER2... | CYNK-101 Pembrolizumab Trastuzumab Recombinant Hum... Cyclophosphamid... Fludarabine Mesna | 18 Years - 75 Years | Celularity Incorporated | |
| UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | NCT01884688 | Asymptomatic Mu... | ENK Cell Infusi... | 18 Years - 75 Years | University of Arkansas | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| PROstaTe Cancer - Exercise-STudy (PRO-TEST) | NCT02954783 | Prostate Cancer | High Intensity ... Usual Care Obse... | 18 Years - | Rigshospitalet, Denmark | |
| Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | NCT01181258 | Non-Hodgkin Lym... Chronic Lymphoc... | Rituximab Interleukin-2 Natural killer ... Cyclophosphamid... Methylprednisol... Fludarabine | - | Masonic Cancer Center, University of Minnesota | |
| GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02321592 | Hodgkin Lymphom... | AFM13 | 18 Years - | University of Cologne | |
| Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS | NCT02477787 | Acute Myelogeno... | allogeneic, don... | 19 Years - 80 Years | Asan Medical Center | |
| Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) | NCT02277587 | Primary Adrenal... Secondary Adren... | Plenadren Conventional gl... | 18 Years - 80 Years | University of Roma La Sapienza | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) | NCT02277587 | Primary Adrenal... Secondary Adren... | Plenadren Conventional gl... | 18 Years - 80 Years | University of Roma La Sapienza | |
| The Clinical Relevance of Immune Cells and CTC in HNSCC Patients | NCT02420600 | Recurrence Metastasis Death | 20 Years - | Chang Gung Memorial Hospital | ||
| Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT01576692 | Neuroblastoma | Humanized anti-... Chemotherapy Cytokines Natural killer ... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation | NCT04796363 | Analgesia Breast Cancer | Erector Spinae ... Standard Genera... | 20 Years - 50 Years | Alexandria University | |
| Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | NCT00990717 | Leukemia Lymphoma Myeloma Hodgkin's Disea... | NK-92 cells | 18 Years - | University Health Network, Toronto | |
| A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | NCT01588769 | Glioblastoma Mu... | ALECSAT cell ba... | 18 Years - | CytoVac A/S | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | NCT00303667 | Acute Myelogeno... | aldesleukin natural killer ... cyclophosphamid... fludarabine pho... allogeneic hema... total body irra... Thymoglobulin Cyclosporin A cyclophosphamid... fludarabine pho... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab | NCT02845999 | Gastrointestina... | allogenic immun... cetuximab Cyclophosphamid... fludarabine interleukin-2 | 18 Years - 65 Years | Centre Hospitalier Universitaire de Besancon | |
| Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT01576692 | Neuroblastoma | Humanized anti-... Chemotherapy Cytokines Natural killer ... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia | NCT00076180 | T-Cell Large Gr... Leukemia, T-Cel... | Hu-MiK-Beta-1 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02321592 | Hodgkin Lymphom... | AFM13 | 18 Years - | University of Cologne | |
| Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) | NCT01106950 | Leukemia, Myelo... | Natural Killer ... Fludarabine Cyclophosphamid... Denileukin dift... Donor lymphaphe... IL-2 | 2 Years - | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | NCT05207722 | Metastatic HER2... | CYNK-101 Pembrolizumab Trastuzumab Recombinant Hum... Cyclophosphamid... Fludarabine Mesna | 18 Years - 75 Years | Celularity Incorporated | |
| Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy | NCT03249727 | Immunity, Innat... Colorectal Canc... | IVDD for NK cel... | 40 Years - | ATGen Canada Inc | |
| Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | NCT01593670 | Myelodysplastic... | Decitabine Vorinostat Interleukin-2 Natural killer ... | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | NCT01593670 | Myelodysplastic... | Decitabine Vorinostat Interleukin-2 Natural killer ... | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | NCT01105650 | Ovarian Cancer Fallopian Tube ... Primary Periton... Breast Cancer | Fludarabine Cyclophosphamid... Cyclosporine Natural killer ... IL-2 Methylprednisol... Methylprednisol... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | NCT04211675 | Relapsed Neurob... Refractory Neur... | Natural Killer ... Temozolomide Irinotecan Dinutuximab Sargramostim | - 29 Years | Nationwide Children's Hospital | |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | NCT00303667 | Acute Myelogeno... | aldesleukin natural killer ... cyclophosphamid... fludarabine pho... allogeneic hema... total body irra... Thymoglobulin Cyclosporin A cyclophosphamid... fludarabine pho... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | NCT03785925 | Urinary Bladder... Neoplasm Metast... | Bempegaldesleuk... Nivolumab | 18 Years - | Nektar Therapeutics | |
| Natural Killer-cell Therapy for Acute Myeloid Leukemia | NCT04347616 | Acute Myeloid L... Acute Myeloid L... | UCB-NK cells IL-2 | 18 Years - | Radboud University Medical Center | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | NCT02130869 | Neuroblastoma Lymphoma High-risk Tumor | CD133+ selected... IL-2 hu14.18K322A Busulfan Melphalan GM-CSF Bendamustine Etoposide Cytarabine Carboplatin Haploidentical ... G-CSF Etoposide phosp... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | NCT04327037 | Leukemia, Acute... Leukemia, Acute... | Expanded Haploi... IL-2 | 1 Year - 30 Years | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | |
| A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients | NCT01588769 | Glioblastoma Mu... | ALECSAT cell ba... | 18 Years - | CytoVac A/S |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
